African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases

PLoS Neglected Tropical Diseases

Volumn 9, Issue 9, 2015, Pages

  Krotneva, Stanimira P ^a   Coffeng, Luc E ^a   Noma, Mounkaila ^b   Zouré, Honorat G M ^b   Bakoné, Lalle ^b   Amazigo, Uche V ^c   de Vlas, Sake J ^a   Stolk, Wilma A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b African Programme for Onchocerciasis Control   (Burkina Faso)

^c Independent Consultant   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; ANTIPARASITIC AGENT;

ARTICLE; ASCARIASIS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE SEVERITY; HEALTH PROGRAM; HOOKWORM INFECTION; HUMAN; LYMPHATIC FILARIASIS; MASS IMMUNIZATION; MATHEMATICAL PHENOMENA; ONCHOCERCIASIS; PARASITIC SKIN DISEASE; PEDICULOSIS; QUALITY ADJUSTED LIFE YEAR; SCABIES; SENSITIVITY ANALYSIS; STREPTOCOCCUS INFECTION; STRONGYLOIDIASIS; TRICHURIASIS; TUNGIASIS; AFRICA; COMPLICATION; DISEASE TRANSMISSION; HELMINTHIASIS; INTESTINAL DISEASES, PARASITIC; PREVALENCE; PREVENTION AND CONTROL;

AFRICA; ANTIPARASITIC AGENTS; DISEASE TRANSMISSION, INFECTIOUS; HELMINTHIASIS; HUMANS; INTESTINAL DISEASES, PARASITIC; IVERMECTIN; ONCHOCERCIASIS; PREVALENCE; SCABIES;

EID: 84943168759     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004051     Document Type: Article

References (73)

1. Amazigo U, (2008) The African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 102 Suppl: 19–22.
2. African Programme for Onchocerciasis Control (2010) Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. Ouagadougou.
3. Coffeng LE, Stolk WA, Zouré HGM, Veerman JL, Agblewonu KB, et al. (2013) African Programme for Onchocerciasis Control 1995–2015: model-estimated health impact and cost. PLoS Negl Trop Dis 7: e2032.
4. Coffeng LE, Stolk WA, Zouré HGM, Veerman JL, Agblewonu KB, et al. (2014) African Programme for Onchocerciasis Control 1995–2015: updated health impact estimates based on new disability weights. PLoS Negl Trop Dis 8: e2759.
5. Campbell WC, (1991) Ivermectin as an antiparasitic agent for use in humans. Ann Rev Microbiol 45: 445–474.
6. Dourmishev AL, Dourmishev LA, Schwartz RA, (2005) Ivermectin: pharmacology and application in dermatology. Int J Dermatol 44: 981–988.
7. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, et al. (2006) Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 367: 1521–1532.
8. Ottesen EA, Hooper PJ, Bradley M, Biswas G, (2008) The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2: e317.
9. Feldmeier H, Heukelbach J, (2009) Epidermal parasitic skin diseases: a neglected category of poverty-associated plagues. Bull World Heal Organ 87: 152–159.
10. Hotez PJ, Kamath A, (2009) Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 3: e412.
11. Brooker S, Hotez PJ, Bundy DAP, (2010) The global atlas of helminth infection: mapping the way forward in neglected tropical disease control. PLoS Negl Trop Dis 4: e779.
12. London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections. www.thiswormyworld.org (Accessed March 30, 2013).
13. Slater H, Michael E, (2013) Mapping, Bayesian Geostatistical Analysis and Spatial Prediction of Lymphatic Filariasis Prevalence in Africa. PLoS One 8: e71574.
14. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197–2223.
15. Hotez PJ, Alvarado M, Basáñez M-G, Bolliger I, Bourne R, et al. (2014) The Global Burden of Disease Study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 8: e2865.
16. Taticheff S, Kebede A, Bulto T, Werkeneh W, Tilahun D, (1994) Effect of ivermectin (Mectizan) on intestinal nematodes. Ethiop Med J 32: 7–15.
17. Tielsch JM, Beeche A, (2004) Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Heal 9: A45–A56.
18. Anosike JC, Dozie INS, Ameh GI, Ukaga CN, Nwoke BEB, et al. (2007) The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria. Ann Trop Med Parasitol 101: 593–600.
19. Gutman J, Emukah E, Okpala N, Okoro C, Obasi A, et al. (2010) Effects of annual mass treatment with ivermectin for onchocerciasis on the prevalence of intestinal helminths. Am J Trop Med Hyg 83: 534–541.
20. Global Burden of Disease Study 2010 visualisation tool. http://www.healthdata.org/data-visualization/gbd-cause-patterns (Accessed March 30, 2013).
21. Yelifari L, Bloch P, Magnussen P, van Lieshout L, Dery G, et al. (2005) Distribution of human Oesophagostomum bifurcum, hookworm and Strongyloides stercoralis infections in northern Ghana. Trans R Soc Trop Med Hyg 99: 32–38.
22. Medley GF, Guyatt HL, Bundy DA, (1993) A quantitative framework for evaluating the effect of community treatment on the morbidity due to ascariasis. Parasitology 106 Pt 2: 211–221.
23. Chan MS, (1997) The global burden of intestinal nematode infections—fifty years on. Parasitol Today 13: 438–443.
24. Bundy DA, de Silva NR, (1998) Can we deworm this wormy world? Br Med Bull 54: 421–432.
25. Noma M, Nwoke BEB, Nutall I, Tambala PA, Enyong P, et al. (2002) Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 96 Suppl 1: S29–S39.
26. Brooker S, Hotez PJ, Bundy DAP, (2008) Hookworm-related anaemia among pregnant women: a systematic review. PLoS Negl Trop Dis 2: e291.
27. U.S. Census Bureau. International database (IDB). www.census.gov (Accessed March 30, 2013).
28. Belizario VY, Amarillo ME, de Leon WU, de los Reyes AE, Bugayong MG, et al. (2003) A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Heal Organ 81: 35–42.
29. Freedman DO, Zierdt WS, Lujan A, Nutman TB, (1989) The efficacy of ivermectin in the chemotherapy of gastrointestinal helminthiasis in humans. J Infect Dis 159: 1151–1153.
30. Naquira C, Jimenez G, Guerra JG, Bernal R, Nalin DR, et al. (1989) Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 40: 304–309.
31. Wen L-Y, Yan X-L, Sun F-H, Fang Y-Y, Yang M-J, et al. (2008) A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China. Acta Trop 106: 190–194.
32. Richard-Lenoble D, Kombila M, Rupp EA, Pappayliou ES, Gaxotte P, et al. (1988) Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections. Am J Trop Med Hyg 39: 480–483.
33. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027.
34. De Silva NR, Guyatt HL, Bundy DA, (1997) Morbidity and mortality due to Ascaris-induced intestinal obstruction. Trans R Soc Trop Med Hyg 91: 31–36.
35. Albonico M, Allen H, Chitsulo L, Engels D, Gabrielli A-F, et al. (2008) Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy. PLoS Negl Trop Dis 2: e126.
36. Moncayo AL, Vaca M, Amorim L, Rodriguez A, Erazo S, et al. (2008) Impact of Long-Term Treatment with Ivermectin on the Prevalence and Intensity of Soil-Transmitted Helminth Infections. PLoS Negl Trop Dis 2: e293.
37. Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW, (1991) A field study of the effect of ivermectin on intestinal helminths in man. Trans R Soc Trop Med Hyg 85: 232–234.
38. Elkins DB, Haswell-Elkins M, Anderson RM, (1988) The importance of host age and sex to patterns of reinfection with Ascaris lumbricoides following mass anthelmintic treatment in a South Indian fishing community. Parasitology 96 (Pt 1): 171–184.
39. Xia ZH, Su YL, Yao SY, Shen BR, Wen LY, et al. (1992) [Clinical observation on efficacy of ivermectin in the treatment of intestinal nematode infections]. Chin J Parasitol Parasit Dis 10: 279–282.
40. Shikiya K, Uehara T, Uechi H, Ohshiro J, Arakaki T, et al. (1991) [Clinical study on ivermectin against Strongyloides stercoralis]. J Japan Assoc Infect Dis 65: 1085–1090.
41. Shikiya K, Kinjo N, Uehara T, Uechi H, Ohshiro J, et al. (1992) Efficacy of ivermectin against Strongyloides stercoralis in humans. Intern Med 31: 310–312.
42. Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M, Gaxotte P, et al. (1994) Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg 88: 344–345.
43. Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, et al. (1996) A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 55: 477–481.
44. Nontasut P, Muennoo C, Sa-nguankiat S, Fongsri S, Vichit A, (2005) Prevalence of strongyloides in Northern Thailand and treatment with ivermectin vs albendazole. Southeast Asian J Trop Med Public Heal 36: 442–444.
45. Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, et al. (2009) Strongyloidiasis—the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg 103: 967–972.
46. Santiago M, Leitão B, (2009) Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view. Eur J Intern Med 20: 744–748.
47. Stern MS, Joshpe G, (1971) Strongyloides stercoralis autoinfection. JAMA 215: 297–298.
48. Plaisier AP, Cao WC, van Oortmarssen GJ, Habbema JD, (1999) Efficacy of ivermectin in the treatment of Wuchereria bancrofti infection: a model-based analysis of trial results. Parasitology 119: 385–394.
49. Dunyo SK, Nkrumah FK, Simonsen PE, (2000) A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Trans R Soc Trop Med Hyg 94: 205–211.
50. Taylor MJ, Hoerauf A, Bockarie M, (2010) Lymphatic filariasis and onchocerciasis. Lancet 376: 1175–1185.
51. Richards FO, Eigege A, Pam D, Kal A, Lenhart A, et al. (2005) Mass ivermectin treatment for onchocerciasis: lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity. Filaria J 4: 6.
52. Kar SK, Mania J, Patnaik S, (1994) The use of ivermectin for scabies. Natl Med J India 7: 15–16.
53. Usha V, Gopalakrishnan Nair T V, (2000) A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 42: 236–240.
54. Sule HM, Thacher TD, (2007) Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. Am J Trop Med Hyg 76: 392–395.
55. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA, (1995) The treatment of scabies with ivermectin. N Engl J Med 333: 26–30.
56. Heukelbach J, Winter B, Wilcke T, Muehlen M, Albrecht S, et al. (2004) Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull World Heal Organ 82: 563–571.
57. Abedin S, Narang M, Gandhi V, Narang S, (2007) Efficacy of permethrin cream and oral ivermectin in treatment of scabies. Indian J Pediatr 74: 915–916.
58. Badiaga S, Foucault C, Rogier C, Doudier B, Rovery C, et al. (2008) The effect of a single dose of oral ivermectin on pruritus in the homeless. J Antimicrob Chemother 62: 404–409.
59. Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA, (2006) Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis 6: 769–779.
60. Gilmore SJ, (2011) Control strategies for endemic childhood scabies. PLoS One 6: e15990.
61. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, et al. (2005) Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Heal Organ 83: 34–42.
62. Feldmeier H, (2009) [Tungiasis and cutaneous larva migrans: unpleasant travel souvenirs]. Med Monatsschr Pharm 32: 440–444.
63. Cestari TF, Pessato S, Ramos-e-Silva M, Tungiasis and myiasis. Clin Dermatol 25: 158–164.
64. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, et al. (2013) Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J 12: 153.
65. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux J-P, (2003) Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2 Suppl 1: S4.
66. Boussinesq M, Kamgno J, Pion SD, Gardon J, (2006) What are the mechanisms associated with post-ivermectin serious adverse events? Trends Parasitol 22: 244–246.
67. Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, et al. (2011) The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.
68. Stolk WA, de Vlas SJ, Borsboom GJJM, Habbema JDF, (2008) LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology 135: 1583–1598.
69. World Health Organization. PCT Databank. www.who.int/neglected_diseases/preventive_chemotherapy (Accessed August 6, 2015).
70. World Health Organization (2006) Preventive chemotherapy in human helminthiasis. Geneva.
71. Knopp S, Mohammed K a, Speich B, Hattendorf J, Khamis IS, et al. (2010) Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin Infect Dis 51: 1420–1428.
72. Uniting to Combat Neglected Tropical Diseases (2012) London Declaration on Neglected Tropical Diseases.
73. Uniting to Combat Neglected Tropical Diseases (2014) Delivering on Promises and Driving Progress.